272 related articles for article (PubMed ID: 32705581)
61. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
[TBL] [Abstract][Full Text] [Related]
62. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
63. The protective effect of Geniposide on diabetic cognitive impairment through BTK/TLR4/NF-κB pathway.
Liu S; Zheng M; Li Y; He L; Chen T
Psychopharmacology (Berl); 2020 Feb; 237(2):465-477. PubMed ID: 31811349
[TBL] [Abstract][Full Text] [Related]
64. Susceptibility to Cryptococcus neoformans Infection with Bruton's Tyrosine Kinase Inhibition.
Messina JA; Giamberardino CD; Tenor JL; Toffaletti DL; Schell WA; Asfaw YG; Palmucci JR; Lionakis MS; Perfect JR
Infect Immun; 2023 Aug; 91(8):e0004223. PubMed ID: 37404186
[TBL] [Abstract][Full Text] [Related]
65. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
66. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
[TBL] [Abstract][Full Text] [Related]
67. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
Lucas F; Woyach JA
Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
[TBL] [Abstract][Full Text] [Related]
68. Acalabrutinib for adults with mantle cell lymphoma.
Jurczak W; Długosz-Danecka M; Wang M
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage.
Shaker ME; Gomaa HAM; Alharbi KS; Al-Sanea MM; El-Mesery ME; Hazem SH
Biomed Pharmacother; 2020 Nov; 131():110736. PubMed ID: 33152913
[TBL] [Abstract][Full Text] [Related]
70. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
71. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
72. Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Siddiqui N; Al-Harbi MM; Attia SM; Bakheet SA
Pharmacol Res; 2019 Oct; 148():104441. PubMed ID: 31505252
[TBL] [Abstract][Full Text] [Related]
73. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
[TBL] [Abstract][Full Text] [Related]
74. Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Fancher KM; Pappacena JJ
Cancer Chemother Pharmacol; 2020 Oct; 86(4):507-515. PubMed ID: 32940733
[TBL] [Abstract][Full Text] [Related]
75. TLX activates MMP-2, promotes self-renewal of tumor spheres in neuroblastoma and correlates with poor patient survival.
Chavali PL; Saini RK; Zhai Q; Vizlin-Hodzic D; Venkatabalasubramanian S; Hayashi A; Johansson E; Zeng ZJ; Mohlin S; Påhlman S; Hansford L; Kaplan DR; Funa K
Cell Death Dis; 2014 Oct; 5(10):e1502. PubMed ID: 25356871
[TBL] [Abstract][Full Text] [Related]
76. BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.
Sun SH; Angell CD; Savardekar H; Sundi D; Abood D; Benner B; DiVincenzo MJ; Duggan M; Choueiry F; Mace T; Trikha P; Lapurga G; Johnson C; Carlson EJ; Chung C; Peterson BR; Lianbo Yu ; Zhao J; Kendra KL; Carson WE
Cancer Immunol Immunother; 2023 Nov; 72(11):3461-3474. PubMed ID: 37528320
[TBL] [Abstract][Full Text] [Related]
77. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM
Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095
[TBL] [Abstract][Full Text] [Related]
78. Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome.
Kröller S; Wissuwa B; Dennhardt S; Krieg N; Thiemermann C; Daniel C; Amann K; Gunzer F; Coldewey SM
Front Immunol; 2023; 14():1105181. PubMed ID: 36911665
[TBL] [Abstract][Full Text] [Related]
79. Targeted Inhibition of ULK1 Promotes Apoptosis and Suppresses Tumor Growth and Metastasis in Neuroblastoma.
Dower CM; Bhat N; Gebru MT; Chen L; Wills CA; Miller BA; Wang HG
Mol Cancer Ther; 2018 Nov; 17(11):2365-2376. PubMed ID: 30166400
[TBL] [Abstract][Full Text] [Related]
80. Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib-findings from three cases.
Blaize M; Thizy G; Boissonnas A; Portalier A; Lanternier F; de La Porte des Vaux C; Suarez F; Bougnoux ME; Guitard J; Jabet A; Stocker N; Aoudjhane A; Roos-Weil D; Fekkar A
Int J Infect Dis; 2024 May; 142():107000. PubMed ID: 38461932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
